Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gulf Pharmaceutical Industries PSC EBITDA Margin % Related Terms
Gulf Pharmaceutical Industries PSC EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADX:JULPHAR vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Gulf Pharmaceutical Industries PSC's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gulf Pharmaceutical Industries PSC EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Gulf Pharmaceutical Industries PSC's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gulf Pharmaceutical Industries PSC's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) has a EBITDA Margin % of 16.61% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. This is 44% above median its historical median of 11.53. According to the industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #25 out of 118 companies in the Medical Distribution industry, placing it in the top 21.2%.
Is Gulf Pharmaceutical Industries PSC's EBITDA Margin % too high?
Gulf Pharmaceutical Industries PSC's current EBITDA Margin % of 16.61% is 44% above median its 10-year median of 11.53. The Medical Distribution industry median EBITDA Margin % is 4.16. Gulf Pharmaceutical Industries PSC's value of 16.61% is 299.8% above this industry median. Based on the distribution chart, Gulf Pharmaceutical Industries PSC ranks #25 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Gulf Pharmaceutical Industries PSC has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gulf Pharmaceutical Industries PSC's EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #25 out of 118 companies for EBITDA Margin %. This places Gulf Pharmaceutical Industries PSC in the top 21% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 4.16. Gulf Pharmaceutical Industries PSC's value of 16.61% is 299.8% above this benchmark. While the company's 10-year median is 11.53 vs. the industry median of 4.16, Gulf Pharmaceutical Industries PSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.16, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gulf Pharmaceutical Industries PSC's current EBITDA Margin % of 16.61% is 299.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gulf Pharmaceutical Industries PSC's current EBITDA Margin % is 16.61%, which is 44% above median its own 10-year median of 11.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gulf Pharmaceutical Industries PSC stock overvalued right now?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) is currently considered Fairly Valued. The stock's GF Value™ is د.إ1.09, compared to a current price of د.إ1.04 — trading 4.6% below its estimated fair value. The current EBITDA Margin % is 16.61%, which is 44% above median its 10-year median of 11.53 and 299.8% above the Medical Distribution industry median of 4.16. Gulf Pharmaceutical Industries PSC's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gulf Pharmaceutical Industries PSC (ADX:JULPHAR), the current EBITDA Margin % is 16.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC stock appears to be undervalued.
The current stock price of د.إ1.04 is trading 4.6% below its estimated GF Value™ of د.إ1.09.
GuruFocus considers Gulf Pharmaceutical Industries PSC to be Fairly Valued.
Key valuation signals for ADX:JULPHAR:
EBITDA Margin %: 16.61% (44% above median its 10-year median of 11.53)
GF Value™: د.إ1.09 vs. price of د.إ1.04 (4.6% below fair value)
Industry Position: 299.8% above the Medical Distribution median (#25 of 118)
No single metric tells the full story. See the ADX:JULPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gulf Pharmaceutical Industries PSC Business Description
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Trading, Investments, and others. The majority of its revenue is generated from the Manufacturing segment. The geographical segments are UAE, Other GCC countries, and Other countries. It derives maximum revenue from UAE. Its business is centered around General Medicines in the retail pharmacy channel and hospitals as well as speciality Products. Its medicines also targets therapeutic segments such as Diabetes, Gastrointestinal Tract (GIT), Respiratory, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Erectile Dysfunction and Others.
54GF Score
Get the complete analysis for ADX:JULPHAR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADX:JULPHAR has been successfully added to your 
